Semaglutide is a peptide. Orforglipron is not. FDA approved Foundayo (orforglipron) on 1 April 2026 as a small-molecule, non-peptide, oral GLP-1 receptor agonist. Same receptor family as peptide GLP-1R agonists. Different chemical class. A research peptide labeled “semaglutide” is not an orforglipron lot, and an orforglipron tablet is not a peptide reagent.
That class split is the fact worth citing. This page does not rank weight-loss programs, does not compare trial percentages, and does not treat a research vial as either drug product.
Two ways to occupy GLP-1R
GLP-1R is a class B GPCR. Endogenous GLP-1 is a peptide. Peptide drugs in this family (semaglutide, liraglutide, and related sequences) are still peptides: amide backbones, sequence identity, proteolytic stability tricks, sometimes fatty-acid acylation. They can be injectable. One of them, oral semaglutide (Rybelsus), is still a peptide. It is formulated for oral use. The molecule did not stop being a peptide because the dose form is a tablet.
Non-peptide (small-molecule) GLP-1 receptor agonists are a different design. They are organic small molecules, not 30-residue chains. Lilly describes orforglipron as a once-daily small molecule (non-peptide) oral GLP-1 receptor agonist. FDA’s 1 April 2026 approval announcement for Foundayo is the primary U.S. regulatory source for that product’s existence as an approved drug. Discovery of the chemotype is credited in Lilly materials to Chugai, with a Lilly license in 2018. Those are origin facts, not catalog copy for a peptide shop.
A lyophilized research peptide is identified by sequence, mass, and HPLC. That toolkit is the wrong toolkit for a non-peptide small molecule. If a COA for a “GLP-1” powder uses a peptide HPLC method and a peptide mass, it is describing a peptide. It is not describing orforglipron. If someone files a small-molecule lot under a peptide nickname, the document is mislabeled. See how to read a peptide COA.
Oral dose form is also not a class test. Rybelsus is oral and still a peptide. Foundayo is oral and not a peptide. “Oral GLP-1” in a headline is therefore ambiguous. Ask whether the molecule is a peptide analogue or a small molecule before you file the citation.
Approved-drug names stay on the approved products
Foundayo is Lilly’s approved orforglipron product, per FDA’s 1 April 2026 announcement. Ozempic, Wegovy, and Rybelsus are Novo Nordisk’s semaglutide products. A research reagent is none of those products. Salt-versus-base for the peptide drugs is a different note: incretin salt forms are not the approved-drug base.
This page will not quote trial weight-change percentages. Those numbers belong in the clinical papers and in the FDA label, not in a reagent catalog’s research notes.
U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program (Foundayo / orforglipron). 1 April 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron)… 1 April 2026. Describes orforglipron as a small molecule (non-peptide) oral GLP-1 receptor agonist.
IUPHAR/BPS Guide to Pharmacology. GLP-1 receptor (GLP-1R).
For laboratory research only. Not for human or veterinary use. This article is not legal advice and not medical advice.
Peptide Incretin vs Non-Peptide Oral GLP-1
Semaglutide is a peptide. Orforglipron is not. FDA approved Foundayo (orforglipron) on 1 April 2026 as a small-molecule, non-peptide, oral GLP-1 receptor agonist. Same receptor family as peptide GLP-1R agonists. Different chemical class. A research peptide labeled “semaglutide” is not an orforglipron lot, and an orforglipron tablet is not a peptide reagent.
That class split is the fact worth citing. This page does not rank weight-loss programs, does not compare trial percentages, and does not treat a research vial as either drug product.
Two ways to occupy GLP-1R
GLP-1R is a class B GPCR. Endogenous GLP-1 is a peptide. Peptide drugs in this family (semaglutide, liraglutide, and related sequences) are still peptides: amide backbones, sequence identity, proteolytic stability tricks, sometimes fatty-acid acylation. They can be injectable. One of them, oral semaglutide (Rybelsus), is still a peptide. It is formulated for oral use. The molecule did not stop being a peptide because the dose form is a tablet.
Non-peptide (small-molecule) GLP-1 receptor agonists are a different design. They are organic small molecules, not 30-residue chains. Lilly describes orforglipron as a once-daily small molecule (non-peptide) oral GLP-1 receptor agonist. FDA’s 1 April 2026 approval announcement for Foundayo is the primary U.S. regulatory source for that product’s existence as an approved drug. Discovery of the chemotype is credited in Lilly materials to Chugai, with a Lilly license in 2018. Those are origin facts, not catalog copy for a peptide shop.
Identity table
What a research peptide COA cannot be
A lyophilized research peptide is identified by sequence, mass, and HPLC. That toolkit is the wrong toolkit for a non-peptide small molecule. If a COA for a “GLP-1” powder uses a peptide HPLC method and a peptide mass, it is describing a peptide. It is not describing orforglipron. If someone files a small-molecule lot under a peptide nickname, the document is mislabeled. See how to read a peptide COA.
Oral dose form is also not a class test. Rybelsus is oral and still a peptide. Foundayo is oral and not a peptide. “Oral GLP-1” in a headline is therefore ambiguous. Ask whether the molecule is a peptide analogue or a small molecule before you file the citation.
Approved-drug names stay on the approved products
Foundayo is Lilly’s approved orforglipron product, per FDA’s 1 April 2026 announcement. Ozempic, Wegovy, and Rybelsus are Novo Nordisk’s semaglutide products. A research reagent is none of those products. Salt-versus-base for the peptide drugs is a different note: incretin salt forms are not the approved-drug base.
This page will not quote trial weight-change percentages. Those numbers belong in the clinical papers and in the FDA label, not in a reagent catalog’s research notes.
Related reading: Semaglutide research overview · GLP-3 is not a receptor · GHRH-axis tools are not incretin agonists
References
For laboratory research only. Not for human or veterinary use. This article is not legal advice and not medical advice.
Last reviewed: 2026-10-15